Efficacy News and Research

RSS

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.

11 Jun 2021

Macrophages can aid tumor growth by distracting cancer-killing CD8+ T cells

A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system's cancer-killing CD8+ T cells.

11 Jun 2021

In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

Researchers in the United States have developed a new coronavirus disease 2019 (COVID-19) vaccine that induced potent neutralizing antibodies against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal models.

10 Jun 2021

Major anti-cancer protein released by neutrophils selectively kills tumor cells

A study published in the June 10, 2021 issue of Cell describes a remarkable new mechanism by which the body's own immune system can eliminate cancer cells without damaging host cells.

10 Jun 2021

ACTG launches phase 1 HIV cure study evaluating two promising therapies

The AIDS Clinical Trials Group, the largest global HIV research network, today announced the launch of A5386, a phase 1 HIV cure study evaluating two promising therapies.

10 Jun 2021

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

In a new study by researchers in the UK, the activity of neutralizing antibodies collected from the sera of individuals that contracted COVID-19 during the first wave of the pandemic is tested against variants of concern the B.1.1.7 (or UK) variant and the B.1.351 (or South African) variant, demonstrating somewhat reduced potency of neutralization towards these strains.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.

9 Jun 2021

Trained dogs can accurately identify COVID-19 by scent

An interesting new medRxiv* preprint reveals that with careful training, the exquisite scent sensitivity of dogs may be exploited to rule out the presence of coronavirus disease 2019 (COVID-19) in human beings in real-time.

9 Jun 2021

SARS-CoV-2 enzyme inhibitors among drugs screened for repurposing

A new bioRxiv* preprint describes the identification of some promising pharmaceutical compounds that could be developed as antiviral drugs against COVID-19.

9 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

An opinion paper by researchers from the US and Italy recently discussed various aspects of monitoring anti-SARS-CoV-2 antibodies before and after receiving COVID-19 vaccination to highlight the pros and cons of this monitoring strategy. This paper is published in the open-access journal Diagnostics.

9 Jun 2021

Microgel-coated mesenchymal stromal cells can reverse pulmonary fibrosis

Researchers at the University of Illinois Chicago have shown that even after lung tissue has been damaged, it may be possible to reverse fibrosis and promote tissue repair through treatment with microgel-coated mesenchymal stromal cells.

9 Jun 2021

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

In a paper recently uploaded to the preprint server medRxiv* by Nakajima et al. (June 4th, 2021), the antibody responses of over 2,000 Japanese healthcare workers were tracked over a period of several months, with particular regard to serum Immunoglobulin G (IgG) against the SARS-CoV-2 spike protein.

8 Jun 2021

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

The report, published in the journal Clinical Infectious Diseases, revealed that the variant detected has been spreading at an alarming rate since November. By February 2021, it accounted for 12.3 percent of all cases in the area.

8 Jun 2021

ONK Therapeutics and Trinity researchers seek to improve cellular therapies for treating cancer

ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has been awarded an Innovation Partnership Programme grant by Enterprise Ireland (EI) to fund collaborative research at Trinity College Dublin, Ireland, led by Dr. David Finlay to optimize the metabolism and engineering of NK cells for improved cancer therapies.

8 Jun 2021

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The study, published in the Journal of Infectious Diseases, determined how circulating antibody levels change after being infected with SARS-CoV-2.

8 Jun 2021

The potential of mRNA vaccines for a wide range of diseases

A new review article published in the journal Briefings in Functional Genomics focuses on the general characteristic features and mechanisms of mRNA vaccines. Further, this review has summarized the current progress of mRNA vaccines that have been developed for wide-ranging diseases, including COVID-19 disease.

8 Jun 2021

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

A new medrxiv* preprint reports on the current landscape of vaccine-induced antibodies in the United Kingdom.

8 Jun 2021

Efficacy News and Research

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

Macrophages can aid tumor growth by distracting cancer-killing CD8+ T cells

In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

Major anti-cancer protein released by neutrophils selectively kills tumor cells

ACTG launches phase 1 HIV cure study evaluating two promising therapies

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

Trained dogs can accurately identify COVID-19 by scent

SARS-CoV-2 enzyme inhibitors among drugs screened for repurposing

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

What are the challenges of SARS-CoV-2 serosurveillance in COVID-19 vaccine recipients?

Microgel-coated mesenchymal stromal cells can reverse pulmonary fibrosis

Potent antibody responses to BNT162b2 COVID-19 vaccine among Japanese healthcare workers

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

ONK Therapeutics and Trinity researchers seek to improve cellular therapies for treating cancer

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The potential of mRNA vaccines for a wide range of diseases

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News